Semaglutide, marketed under the brand names Ozempic, Wegovy, and Rybelsus, is a GLP-1 agonist available in various forms, including weekly injections (Ozempic for diabetes and Wegovy for obesity) and daily oral tablets (Rybelsus)
If you already feel weak, dizzy, or like you are barely eating, read eating too little on Ozempic or GLP-1 medication
However, compounded versions of semaglutide may not be widely be available after May 2025 due to the FDAs recent declaration that the semaglutide shortage has ended
This variability underscores the complexity of predicting and understanding the drugs impact on sleep for each patient
Abstract Glucagon, once seen as an insulin counter-regulatory hormone, is now recognized as a key regulator of systemic energy balance, with expanding relevance across a spectrum of cardiometabolic diseases